IP Library Granted Patent US 12,290,654
Granted Patent B2
US 12,290,654 · App. 17/741,651 · Granted May 6, 2025

Using alternating electric fields to increase permeability of the blood brain barrier

Inventors: Carsten Hagemann (Unterpleichfeld, DE); Mario Lohr (Dillenburg, DE); Almuth F. Kessler (Reichenberg, DE); Malgorzata Burek (Wurzburg, DE); Carola Forster (Wurzburg, DE); Catherine Brami (Matan, IL); Hadas Sara Hershkovich (Kiryat Motzkin, IL); Tali Voloshin-Sela (Haifa, IL)
Assignee: Novocure Gmbh
A61M37/0092A61K9/0009A61N1/325A61N1/327A61N1/36002A61N1/3603A61N1/37217A61K9/0085A61M2037/0007A61M2202/0007A61M2210/0693A61M2250/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,654
App. No.
17/741,651
Granted
May 6, 2025
Kind
B2
Abstract

Certain substances (e.g., large molecules) that ordinarily cannot traverse the blood brain barrier can be introduced into the brain by applying an alternating electric field to the brain for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the blood brain barrier. In some embodiments, the frequency of the alternating electric field is less than 190 kHz (e.g., 100 kHz). Once the permeability of the blood brain barrier has been increased, the substance is able to cross the blood brain barrier.

Claims (25)

1. A method for delivering a substance across a blood brain barrier of a subject's brain, the method comprising:

applying an alternating electric field at a first frequency to the subject's brain for a period of time, wherein the subject's brain is tumor-free, wherein the first frequency is between 50 kHz and 190 kHz, and wherein application of the alternating electric field at the first frequency to the subject's brain for the period of time increases permeability of the blood brain barrier in the subject's brain; and

administering the substance to the subject, wherein the increased permeability of the blood brain barrier allows the substance to cross the blood brain barrier,

wherein the period of time is at least 24 hours and the substance is administered to the subject after the period of time has elapsed.

2. The method of claim 1 , wherein the alternating electric field is applied at a frequency between 75 kHz and 125 kHz,

wherein the alternating electric field has a field strength of at least 1 V/cm in at least a portion of the subject's brain.

3. A method of delivering a substance across a biological barrier in a subject's body, the method comprising:

applying an alternating electric field to the biological barrier in a portion of the subject's body for a period of time, wherein the alternating electric field has a frequency between 50 kHz and 190 kHz, and wherein application of the alternating electric field for the period of time increases permeability of the biological barrier; and

administering the substance to the subject, wherein the increased permeability of the biological barrier allows the substance to cross the biological barrier,

wherein the portion of the subject's body is tumor-free,

wherein the period of time is at least 24 hours and the substance is administered to the subject after the period of time has elapsed, and

wherein the alternating electric field has a field strength of at least 1 V/cm in at least a part of the portion of the subject's body.

4. A method of delivering a substance across a biological barrier in a subject's body, wherein the biological barrier includes endothelial cells and tight junction proteins located between the endothelial cells, the method comprising:

applying an alternating electric field to the endothelial cells in a portion of the subject's body for a period of time, wherein the alternating electric field has a frequency between 50 kHz and 190 kHz, and wherein application of the alternating electric field for the period of time causes delocalization of the tight junction proteins; and

administering the substance to the subject, wherein the delocalization of the tight junction proteins allows the substance to cross the biological barrier,

wherein the portion of the subject's body is tumor-free, and

wherein the substance is administered after the period of time has elapsed.

5. The method of claim 4 , wherein the alternating electric field has a field strength of at least 1 V/cm in at least a part of the portion of the subject's body.

6. The method of claim 4 , wherein the period of time is at least 24 hours, and the alternating electric field has a field strength of at least 1 V/cm in at least a part of the portion of the subject's body.

7. The method of claim 4 , wherein the tight junction proteins include claudin.

8. The method of claim 4 , wherein the tight junction proteins include claudin-5.

9. The method of claim 4 , wherein the tight junction proteins include ZO-1.

10. The method of claim 4 , wherein the substance is administered at least 24 hours after the applying of the alternating electric field has begun.

11. The method of claim 4 , wherein the substance is administered within 96 hours of when the period of time elapsed.

12. The method of claim 4 , wherein the substance has a molecular weight between 4 kDa and 69 kDa.

Assignments (4)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: HAGEMANN, CARSTEN; LOHR, MARIO; KESSLER, ALMUTH F.; BUREK, MALGORZATA; FORSTER, CAROLA
To: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG
Reel/Frame 060080/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG
To: NOVOCURE GMBH
Reel/Frame 060080/0454 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2022
From: BRAMI, CATHERINE; HERSHKOVICH, HADAS SARA; VOLOSHIN-SELA, TALI
To: NOVOCURE GMBH
Reel/Frame 060080/0522 →
Continuity (3)
Continuation 16548514 · Aug 22, 2019
Provisional Application 62722100 · Aug 23, 2018
Related Publication 20220265982A1 · Aug 25, 2022
References Cited (97)
US 6868289B2 · Palti · 2005 [cited by applicant]
US 7016725B2 · Palti · 2006 [cited by applicant]
US 7089054B2 · Palti · 2006 [cited by applicant]
US 7136699B2 · Palti · 2006 [cited by applicant]
US 7146210B2 · Palti · 2006 [cited by applicant]
US 7333852B2 · Palti · 2008 [cited by applicant]
US 7467011B2 · Palti · 2008 [cited by applicant]
US 7519420B2 · Palti · 2009 [cited by applicant]
US 7565205B2 · Palti · 2009 [cited by applicant]
US 7565206B2 · Palti · 2009 [cited by applicant]
US 7599745B2 · Palti · 2009 [cited by applicant]
US 7599746B2 · Palti · 2009 [cited by applicant]
US 7706890B2 · Palti · 2010 [cited by applicant]
US 7715921B2 · Palti · 2010 [cited by applicant]
US 7758561B2 · Eppstein · 2010 [cited by applicant]
US 7805201B2 · Palti · 2010 [cited by applicant]
US 7890183B2 · Palti et al. · 2011 [cited by applicant]
US 7912540B2 · Palti · 2011 [cited by applicant]
US 7917227B2 · Palti · 2011 [cited by applicant]
US 8019414B2 · Palti · 2011 [cited by applicant]
US 8027738B2 · Palti · 2011 [cited by applicant]
US 8170684B2 · Palti · 2012 [cited by applicant]
US 8175698B2 · Palti et al. · 2012 [cited by applicant]
US 8229555B2 · Palti · 2012 [cited by applicant]
US RE43618E · Palti · 2012 [cited by applicant]
US 8244345B2 · Palti · 2012 [cited by applicant]
US 8406870B2 · Palti · 2013 [cited by applicant]
US 8447395B2 · Palti et al. · 2013 [cited by applicant]
US 8447396B2 · Palti et al. · 2013 [cited by applicant]
US 8465533B2 · Palti · 2013 [cited by applicant]
US 8706261B2 · Palti · 2014 [cited by applicant]
US 8715203B2 · Palti · 2014 [cited by applicant]
US 8718756B2 · Palti · 2014 [cited by applicant]
US 8764675B2 · Palti · 2014 [cited by applicant]
US 8926606B2 · Davalos et al. · 2015 [cited by applicant]
US 9023090B2 · Palti · 2015 [cited by applicant]
US 9023091B2 · Palti · 2015 [cited by applicant]
US 9039674B2 · Palti et al. · 2015 [cited by applicant]
US 9056203B2 · Palti et al. · 2015 [cited by applicant]
US 9198733B2 · Neal et al. · 2015 [cited by applicant]
US 9440068B2 · Palti et al. · 2016 [cited by applicant]
US 9655669B2 · Palti et al. · 2017 [cited by applicant]
US 9750934B2 · Palti et al. · 2017 [cited by applicant]
US 9910453B2 · Wasserman et al. · 2018 [cited by applicant]
US 10188851B2 · Wenger et al. · 2019 [cited by applicant]
US 10441776B2 · Kirson et al. · 2019 [cited by applicant]
US 20020193833A1 · Dimmer et al. · 2002 [cited by applicant]
US 20030158589A1 · Katsnelson · 2003 [cited by applicant]
US 20030171738A1 · Konieczynski et al. · 2003 [cited by applicant]
US 20030191506A1 · Shloznikov · 2003 [cited by applicant]
US 20040010290A1 · Schroeppel et al. · 2004 [cited by applicant]
US 20060149337A1 · John · 2006 [cited by applicant]
US 20060276858A1 · Palti · 2006 [cited by applicant]
US 20100049117A1 · Bragagna et al. · 2010 [cited by applicant]
US 20110046540A1 · Alterman et al. · 2011 [cited by applicant]
US 20110079513A1 · Stelzle et al. · 2011 [cited by applicant]
US 20120310140A1 · Kramer et al. · 2012 [cited by applicant]
US 20120323214A1 · Shantha · 2012 [cited by applicant]
US 20140039489A1 · Davalos et al. · 2014 [cited by applicant]
US 20140154244A1 · Desai et al. · 2014 [cited by applicant]
US 20140330268A1 · Palti et al. · 2014 [cited by applicant]
US 20150126964A1 · Martel et al. · 2015 [cited by applicant]
US 20170215939A1 · Palti et al. · 2017 [cited by applicant]
US 20170281934A1 · Giladi et al. · 2017 [cited by applicant]
US 20180001075A1 · Kirson et al. · 2018 [cited by applicant]
US 20180008708A1 · Giladi et al. · 2018 [cited by applicant]
US 20180021217A1 · Tracey et al. · 2018 [cited by applicant]
US 20180050200A1 · Wasserman et al. · 2018 [cited by applicant]
US 20180160933A1 · Urman et al. · 2018 [cited by applicant]
US 20180202991A1 · Giladi et al. · 2018 [cited by applicant]
US 20190117956A1 · Wenger et al. · 2019 [cited by applicant]
US 20190298982A1 · Story et al. · 2019 [cited by applicant]
US 20190307781A1 · Krex et al. · 2019 [cited by applicant]
US 20190308016A1 · Wenger et al. · 2019 [cited by applicant]
US 20200001069A1 · Kirson et al. · 2020 [cited by applicant]
US 20200009376A1 · Chang et al. · 2020 [cited by applicant]
US 20200009377A1 · Chang et al. · 2020 [cited by applicant]
US 20200016399A1 · Kaynan et al. · 2020 [cited by applicant]
US 20210016084A1 · Mardor et al. · 2021 [cited by applicant]
CN 1206353A · 1999 [cited by applicant]
CN 104602759A · 2015 [cited by applicant]
CN 112469352A · 2021 [cited by applicant]
EP 1502623A1 · 2005 [cited by applicant]
WO 2016164930A1 · 2016 [cited by applicant]
WO 2016179712A1 · 2016 [cited by applicant]
Arena et al., “Focal blood-brain-barrier disruption with high-frequency pulsed electric fields,” Technology, vol. 2, No. 3, Jul. 2014. [cited by applicant]
Bonakdar et al., “A microfluidic model of the blood-brain barrier to study permeabilization by pulsed electric fields,” RSC Advances, vol. 7, pp. 42811-42818, 2017. [cited by applicant]
Chang et al., “Tumor treating fields increases membrane permeability in glioblastoma cells,” Cell Death Discovery, 4:113, 2018. [cited by applicant]
Chang et al., “Tumor treating fields increases membrane permeability in glioblastoma cells,” Proceedings of the 110th Annual Meeting of the American Association for Cancer Research, Mar. 29-Apr. 3, 2019, Atlanta, Georgi… [cited by applicant]
International Search Report and Written Opinion issued in application No. PCT/IB2019/057091 dated Dec. 17, 2019. [cited by applicant]
Kessler et al., “Effects of Tumor Treating Fields (TTFields) On Blood Brain Barrier (BBB) Permeability,” Neuro. Onc., vol. 20, Suppl. 6, vi93-vi94, Nov. 2018. [cited by applicant]
Kessler et al., “Effects of Tumor Treating Fields (TTFields) on blood brain barrier permeability,” Neuro. Onc., vol. 20, Suppl. 3, p. 286, Sep. 2018. [cited by applicant]
Kessler et al., “Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition,” Cell Death Discovery, 5:12, 2019. [cited by applicant]
Kessler et al., “Tumor treating fields (TTFields) affect the blood brain barrier (BBB) integrity in vitro and in vivo, Proceedings of the 110th Annual Meeting of the American Association for Cancer Research,” Mar. 29-Ap… [cited by applicant]
Bonakdar et al., “Electroporation of Brain Endothelial Cells on Chip toward Permeabilizing the Blood-Brain Barrier,” Biophysical Journal, vol. 110, pp. 503-513, Jan. 2016. [cited by applicant]
Hjouj et al., “MRI Study on Reversible and Irreversible Electroporation Induced Blood Brain Barrier Disruption,” PLOS One, vol. 7, Issue 8, p. e42817, Aug. 2012. [cited by applicant]
Stupp et al., “Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs. Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial,” JAMA, vol. 318, pp. 2306-2316, 201… [cited by applicant]